Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 16

HR=0.76 (95% CI: 0.67-0.86)
% Event -Free
60
40
20
0
0
2
4
6
8
10
P<0.0001
0
1
2
3
4
5
P=0.016
Without T
With T
100
80
41.9%
28.8%
% Event -Free
60
40
20
0
100
80
Years from Randomization
HR=0.64 (95% CI: 0.44-0.93)
Without T
With T
Years from Randomization
Neoadjuvant
NOAH
Event-Free Survival
L. Gianni et al, ASCO Annual Meeting 2013
Adjuvant
HERA
Disease-Free Survival
Unmet Medical Need Remains in HER2+ EBC
Roche data on file.
1...,6,7,8,9,10,11,12,13,14,15 17,18,19,20,21,22,23,24,25,26,...47
Powered by FlippingBook